



सत्यमेव जयते



क.रा.बी.नि.  
**ESIC**

**कर्मचारी राज्य बीमा निगम**

(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)

**EMPLOYEES' STATE INSURANCE CORPORATION**  
(Ministry of Labour & Employment, Govt. of India)

**DG-ESIC CENTRAL RATE CONTRACT NO. – 161**  
**FOR SUPPLY OF DRUGS**

(VALID FROM 8<sup>th</sup> APRIL, 2025 to 7<sup>th</sup> APRIL, 2027)

ANTI CANCER AND IMMUNOSUPPRESANT DRUGS

VACCINES

IMMUNOGLOBULIN

STRICTLY FOR OFFICIAL USE

**मुख्यालय/HEADQUARTERS'**

कमरा नंबर 312 और 321, तीसरी मंजिल, पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002

Room No. 312 & 321, 3<sup>rd</sup> Floor, Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002

[www.esic.gov.in](http://www.esic.gov.in), ☎ 011-23604773, ✉ [dmc-rc@esic.nic.in](mailto:dmc-rc@esic.nic.in)

2025-2027

*(Handwritten Signature)*

| Page



S.No.	Contents	Page No.
1.	Forwarding letter along with terms & conditions for operation of Rate Contract No. 161	1-12
2.	List of Approved Pharmaceutical firms of Rate Contract No. 161	13-17
3.	Indexing of approved Items	18-24
4.	Rate Schedule of Rate Contract No. 161	25-49

क.रा.बी.नि.  
ESIC

**STRICTLY FOR OFFICIAL USE ONLY**



कर्मचारी राज्य बीमा निगम  
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)  
EMPLOYEES' STATE INSURANCE CORPORATION  
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS'  
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002  
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 [www.esic.gov.in](http://www.esic.gov.in),  
☎011-23604773, ✉ [dmc-rc@esic.gov.in](mailto:dmc-rc@esic.gov.in)

No. U-25/12/RC/159TO163/2022-Med.V (E-117064)/161

Dt: 8<sup>th</sup> April 2025

From:

The Director General,  
E.S.I. Corporation,  
Panchdeep Bhawan,  
C.I.G Road,  
NEW DELHI - 110 002.

To

Director (Medical) Delhi/Noida  
Dean-PGIMSR's/ All ESIC Medical Colleges & Hospitals/Dental Colleges  
Medical Superintendent – All ESIC & ESIS Hospitals,  
Director, ESI Scheme – All States & UTs.

Sub:

**PROCUREMENT OF DRUGS UNDER ESIC CENTRAL RATE CONTRACT NO. 161  
EFFECTIVE FROM 08.04.2025 TO 07.04.2027.**

Sir / Madam,

Please find enclosed a copy of the DG-ESIC Centralized Rate Contract duly adhering to Public Procurement (Preference to Make in India) Order, 2017 (as amended and revised till date) and related notifications from the relevant Nodal Ministry/ Department, finalized for supply of Drugs under the ESI Scheme in the country.

**Validity of this Rate Contract is for a period of two years i.e. w.e.f. 08.04.2025 TO 07.04.2027.**

Further, the following terms & conditions are issued to govern operation of the Rate Contract:-

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers- Medical Superintendent/Dean/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his/her behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.



2. Supply orders will be placed by Medical Superintendents/Deans/Director, Insurance Medical Services of various States, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and / or wherever specifically provided in the terms & conditions of the Rate Contract. The Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract.
3. All the supply orders shall be signed only by the officers who have been duly authorised and included in the list of DDOs. DDOs will send **scanned copy of the Purchase Order mandatorily through email followed by speed post directly to the Approved Pharmaceutical Firm**. The due date of delivery will be counted from the date of issuance of purchase order via email. It shall be the responsibility of DDOs to monitor the activity of placing purchase order via email/online module.
4. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them.
5. The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report along with the comments and details as under: -

**PROFORMA FOR NON-SUPPLY REPORT**

R.C. No.	Item No. & Name of Drug	Name of firm	S.O. No. with Date	Preference (L1/L2/L3)	Qty. not supplied	Risk Purchase/ penalty levied	Payment if pending	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.

6. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.
7. It will be ensured before placing order by the Direct Demanding Officer that necessary funds are available and **payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.**
8. Supply orders/Purchase order(s) will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.



9. No guarantee can be given as to the minimum quantity which will be drawn against this contract but the approved Pharmaceutical firm will supply quantity as may be ordered by the Direct Demanding Officers during the currency of the contract.
10. The approved Pharmaceutical firm will supply the items immediately on demand or latest within six weeks of placing of supply order throughout the period of contract.
11. Supply orders/Purchase orders against the contract will be accepted as long as these reach the approved Pharmaceutical firm on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.
12. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm to supply the item as per the specifications of the relevant rate contract.

### **SUPPLIES**

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.
14. During transit approved Pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.
15. The prices approved are F.O.R. Destination per unit and are exclusive of GST except where indicated but inclusive of all charges for packing and forwarding.
16. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.
17. **The approved** Pharmaceutical firm will have to supply drugs directly in the quantity ordered, to ESIC or ESIS Institutions. The approved Pharmaceutical firm shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons. In case, at any stage of the contract, it is found that the approved Pharmaceutical firm has appointed the distributors/dealers/third party agent for making supply or receiving of supply order against the contract, ESI Corporation will initiate the following actions against the approved Pharmaceutical firm(s):



- a. 100% forfeiture of Performance Security from the valid current all DG-ESIC Rate Contract(s).
- b. Blacklisting for participation in the future tender enquiries for all ESI Institutions for a period of two years prospectively.

18. Marking:

Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

19. Packing:

- a) It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted/rubber stamping with indelible ink clearly. Any consignment without such stamping will not be considered valid and will be rejected.
- b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.
- c) Supplies to be made in proper boxes.
- d) Liquid orals to be supplied only in glass/ plastic bottles conforming to Drugs & Cosmetics Act and rules made there under.
- e) Large volume parenterals to be supplied only in plastic bottles / polypacks conforming to Drugs & Cosmetics Act and rules made there under.
- f) It should be ensured that only **first use packaging material of uniform size including Bottles and vials** should be used for making supplies on the basis of ESI Rate Contract.
- g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.
- h) Packing should be able to prevent damage or deterioration during transit.
- i) All containers i.e. bottle, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents. MRP should not be written on any labels otherwise it will be disqualified.
- j) All DGESIC approved pharmaceutical firm will make supply bearing Quick response code on its label at each level packaging that store data or information readable with software application to facilitate tracking and tracing as per Gazette Notification and CDSCO guidelines time to time.



**20. Life Period :**

I:

- a) For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
- b) For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.
- c) Imported Drugs: As on the date of delivery, Drugs should have a minimum 50% of valid shelf life from the date of manufacture.

II.

Notwithstanding the above, DDOs/Authorized nominated officer by DDO may relax this criteria in case of exigencies with reasons duly recorded and shall be responsible for use of that stores within its given shelf life, with a suitable undertaking from the supplier, the terms of which shall be decided by the consignee as per the requirement of the stores and usage pattern. The Consignee should ensure that there should not be any financial loss to the Corporation.

**21. Pharmacopoeia Specifications:**

Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation supplied as per the provisions of Drug and Cosmetics Act.

22. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.

23. It should be ensured that ISI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has ISI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards.

**24. Testing of Drugs – Quality Control**

- a. Approved Rate Contract Holder should mandatorily submit a Test Report for that particular batch of medicines tested by the Government/Government approved Laboratories along with each supply, failing which supply received will be liable for rejection at the inspection stage and penalty of late supply will be levied as per provisions.
- b. Regular testing of 10% of supplies of drugs received in a month will be under taken by ESI from Govt./Govt. approved laboratories. Additional quality testing may also be undertaken by ESI Institutions at any time during the shelf life or whenever any defect is noticed.



- c. Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the approved Pharmaceutical firm/ firms at regular interval to maintain and ensure the quality of drugs.
- d. Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.
- e. The report of the Govt./Govt. approved laboratory shall be accepted by the approved Pharmaceutical firm. In case the same is disputed by the approved Pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However, the same should be submitted **within three months**, from the date of communication of the disputed test report to the approved Pharmaceutical firm. For this, the approved Pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory **at their own cost**. In case no response is received from the approved Pharmaceutical firm within the stipulated period, action as deemed fit as per terms & conditions of the Rate Contract will be initiated.
- f. For imported items: - The approved Pharmaceutical firm must submit the In-house test report of Principal manufacturer with each and every batch of supply.
- g. If any drug/s supplied against this Rate Contract are found to be "Not of Standard Quality" on inspection by Competent Authority, the approved Pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the approved Pharmaceutical firm/s.
- h. If the product is found to be "Not of Standard Quality", the cost of testing will be recovered from the approved Pharmaceutical firms and further action will be taken as per clause no. 25 mentioned below:
25. The classification of defects into different categories is as per the guidelines issued by the Drugs Controller General (India), Central Drugs Standard Control Organization (CDSCO) & action will be taken by ESIC for each category of defects, described as below: -
- A. CATEGORY 'A' DEFECT (Spurious / Adulterated Drugs)-**
- If any item / Batch of the item declared Not of Standard quality (NSQ) under Category A .**
- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Recoveries to be initiated by the DDO's wherever payment had been made already.
  - **100% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for all the quoted drugs.



- Debarring of the Rate Contract holder /approved Pharmaceutical firm from current and all future DGESIC Rate Contract for participation in tender enquiry of all ESIC institutions prospectively for a period of two years.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

#### **B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs)**

##### **1. If single item/ Batch of item is declared NSQ under Category B**

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **20% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for that drug as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item.
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

##### **2.**

##### **a) If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category B**

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **50% (20% + 30%) Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2<sup>nd</sup> NSQ) as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- **Any subsequent (3<sup>rd</sup> onwards) NSQ reported** of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current and all future DGESIC Rate Contracts for a period of two years for participation in all ESI Institutions prospectively along with forfeiture of **100% performance security for all NSQ declared items.**

- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
- b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category B within a year**
- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **100% Forfeiture of Performance Security from the respective DGESIC Rate Contract for this item (2<sup>nd</sup> NSQ) as per clause 13(III) of TE.**
- Debarring of Rate Contract Holder/approved Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for the item for a period of two years for participation in all ESI Institution prospectively.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

#### **C. CATEGORY ' C ' DEFECT (Minor Defects)**

##### **1.If single item/ Batch of item is declared NSQ under Category C**

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

**2.**

##### **a)If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category-C.**

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Warning to be issued to the firm for the NSQ item.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

##### **b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category C within a year.**



- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **10% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2<sup>nd</sup> NSQ) as per clause 13(III) of TE.
- **Any subsequent (2<sup>nd</sup> NSQ onwards) NSQ** reported of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current DGESIC Rate Contracts.
- Warning to be issued to the firm for the NSQ item
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

26. **Delivery Period – Risk Purchase**

- a. Delivery period will be of six weeks from the date of **issuance of purchase order via email** and the approved Pharmaceutical firm shall execute the order within stipulated time.
- b. If the approved Pharmaceutical firm fails to execute the supply order within the stipulated period of six weeks, a penalty of two (2) percent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. An approved Pharmaceutical firm can seek extension of the delivery period with the prior consent of the Direct Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. The extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned DDO.
- c. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other approved Pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate or from local chemist. All DDOs of ESIC & ESIS Institutions shall record each instance of Non-Supply of respective approved Pharmaceutical Firm and a consolidated quarterly non-supply report to be submitted at ESIC HQRS.

**Extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.**



- d. i) If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of approved Pharmaceutical firm. **The extra expenditure involved in procuring supplies from elsewhere i.e. L2 firm/other running Govt. Contract/ Local Purchase etc. will be recoverable from the approved Non-supplying Pharmaceutical firm, in full by Direct Demanding Officers.**
- ii) The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with bidder by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the bidder's Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than two years.
- e. If the approved Pharmaceutical firm fails to execute the supply order three times at any location of ESIC & ESIS in any part of the country during the period of rate contract, it shall be debarred for the next two years with effect from the last failure and forfeiting of Performance Security for that drug.

#### 27. Payment

Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm/bidder to supply the items as per the specifications of the relevant rate contract. No claim for the payment from contractor shall be entertained after the lapse of three years of arising of the claim.

28. Any dues or payments that have arisen to the Corporation from the approved Pharmaceutical firm for which no specific time limit has been laid down in the terms and conditions shall be payable by the approved Pharmaceutical firm within such time limit as may be prescribed in the letters/orders addressed to the approved Pharmaceutical firms.
29. Any payments that have been demanded as per the provisions of above-mentioned clause or under any other clause shall be payable within the time laid down. On failure to do so:
- The approved Pharmaceutical firm shall be liable to be debarred for supplying items/ drugs etc. to the Corporation for a period not exceeding two years.
  - The Corporation reserves its right to take appropriate legal action against the defaulting firms as may be legally advised, including claim for compensation and damages for the period of delay and / or simple interest 10% per annum for each day of default.





30. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed: -  
(a) Items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.  
(b) In case of items, where two approved Pharmaceutical Firms exist at L-1(1<sup>st</sup> Preference), it is mandatory for all Direct Demanding Officers (DDOs) to place Supply Orders in the ratio of 50% of the order quantity to each L-1 approved Pharmaceutical firm on each instance of placing of supply order in adherence to Public Procurement (Preference to Make in India) Order, 2017 guidelines issued vide order dated 16.09.2020.
31. No other document should be entertained for giving any cognizance for placing the supply orders.
32. The validity of the contract of approved Pharmaceutical firm holding Patent right of approved drug/s in the currency of Rate Contract shall be for two years or till date of expiry of patent whichever is earlier. It is the sole responsibility of the patent holding firm to mandatorily inform ESIC Ten days before the expiry of the Patent of the approved drug/s in Rate Contract, failing which the participating firm shall be blacklisted in the participating and prospective RCs for a period of two years alongwith forfeiture of EMD/ Performance security (as the case may be) as per Terms & Conditions of the Tender Enquiries.
33. The Letter of Award issued to the firms by this office cannot be used for placing orders.
34. Standing Committee on Government e-Market (SCoGeM), Ministry of Labour & Employment has granted exemption to publish and operate DG-ESIC Rate Contract for the Drugs other than drugs reserved for CPSUs.
35. Force Majeure:  
If at any time during the applicability of Contract the bidder fails to discharge its Obligation due to force majeure (natural disaster or act of God etc.) he will promptly notify the Director General or its representative about the happening of such an event. The Director General or its representative is solely entitled to terminate/ determine the order/contract in respect of such performance of the bidder(s) obligations if he so desires. The obligations under the contract on behalf of bidder for the contract shall be resumed as soon as practicable after the event has come to an end or ceased to exist.

36. It shall be the sole responsibility of Medical Superintendents/Deans/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO/ Head of Institutions of respective State to maintain an optimum Inventory level with strict control as per ABC-VED matrix and ensure the drug formulary of the respective institution is followed in right earnest to provide medical services to ESI Beneficiaries.
37. All Deans/MSs/ DIMS/ Head of ESIC & ESIS Institutions are requested to keep a vigilant check on procurement of drugs in order to avoid obsolescence/expiry/excessive procurement of drugs resulting in infructuous expenditure.

**This issue with the approval of Competent Authority.**

Yours faithfully,

Encl.: As above.

  
(Dr. Sanjiv Kochhar)  
Dy. Medical Commissioner (RC)  
For: DIRECTOR GENERAL

Copy to:

1. PPS/PS to Director General, ESIC for information.
2. PPS/PS to Finance Commissioner for information.
3. PPS/PS to Medical Commissioner (Procurement/ Medical Services/ Medical Education / Medical Administration) for information.
4. Accounts Branch – V (Hqrs. Office)
5. All Chief Direct Demanding Officers (In-Charge) of ESIC and ESI Scheme of all States/UT's for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.
6. Website Content Manager for uploading on ESIC HQRS Website.
7. Guard File.

  
उप चिकित्सा आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

  
Dy. Medical Commissioner (RC)  
For: DIRECTOR GENERAL

उप चिकित्सा आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)





## List of Approved Pharmaceutical firms of Rate Contract No. 161

S.N.	RC No.	Name of the Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)	Address of Approved Pharmaceutical Firm
1	161	Bajaj Healthcare Limited	9324291478, 022-66177400, 022-66177458, marketing@bajajhealth.com, shantaram@bajajhealth.com	602-606, 6th Floor, Bhoomi Velocity Infotech Park, Plot No: B-39, Road No. 23, Above ICICI Bank, Wagle Industrial Estate, Thane (W)-400604
2	161	Baxter India Pvt Ltd	7829415085, 0124-4500200, baxsolutions_india@baxter.com	5th Floor, Tower-A, Building No. 9, DLF Cyber City, DLF Phase III, Gurgaon-122002, Haryana
3	161	Bharat Serums And Vaccines Limited	9967657228, 022-45043456, 022-45043200, institution@bsvgroup.com, niti.n.nagar@bsvgroup.com	3rd floor, Liberty Towers, Plot No. K-10, Behind Reliable Plaza, Kalwa Industrial Estate, Airoli, Navi Mumbai - 400708
4	161	Biocon Biologics Limited	9820407013, 080 67751329, 080 67751320, marketaccess.bbl@biocon.com	Biocon House, Tower-3, Smicon Park, Electronic City, Phase 2, Hosur Road, Bengaluru - 560100
5	161	Biodeal Pharmaceuticals Ltd.	88021 37137, 0120-6025048, 7428744221, institution1@biodealpharma.com, Institution@biodealpharma.com	Vill. Saini Majra, Nalagarh Ropar Road Nalagarh, Solan, Himachal Pradesh 174101
6	161	Cipla Ltd.	+91 7506003699, 022 24826000, 022 24826120, +91 9506692389, Institution@Cipla.com, ketan.chaudhari@cipla.com, prashant.gupta1@cipla.com	Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, lower Parel, Mumbai- 400 013
7	161	Concord Biotech Limited	7573036632, 7968138700, 796 8138725, 9830486374, tenderbusiness@concordbiotech.com, baijuvarghese@concordbiotech.com	1601-1602, B-Wing, Mondeal Heights, Isckon Cross Road, S G Highway, Ahmedabad 380015 Gujarat



## List of Approved Pharmaceutical firms of Rate Contract No. 161

8	161	Dr. Reddy's Laboratories Limited	9000995868 & 9154302501,040 49048400,040 49048800, 9000995868 & 9154302501 , ibtpricing@drreddys.com,ibt@drreddys.com	7-1-27, Ameerpet, Hyderabad 500016, Telangana, India
9	161	Eli Lilly and Company (India) Pvt. Ltd.	9910897355,0124-4753000,0124-4753012, singh_inderpal@lilly.com,tendersinfo@lilly.com	Plot No. 92, Sector 32, Gurgaon - 122001, Haryana
10	161	Fresenius Kabi India Private Limited	9049275533, 020 67649000,9049275533, jatish.kumar@fresenius-kabi.com,instkabi@fresenius-kabi.com,Mohammad.alim@fresenius-kabi.com,instkabi@fresenius-kabi.com	Ninth Floor, AP 81, S No 83, North Main Road, Near Hard Rock Cafe, Mundhwa, Pune 411036, Maharashtra, India. Tel: +91 20 67649000
11	161	Getwell Pharma India Private Limited	70651 05826,124-4477981/82,0124-4477986,70651 05826, ruchi@getwelloncology.com	474, Udyog Vihar, Phase V, Gurgaon - 122016 (Haryana)
12	161	Intas Pharmaceuticals Ltd	9810824433, 079-39837000, 9810824433, abhishek_bajaj@intaspharma.com	Intas Pharmaceuticals Limited, Corporate House, Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad- 380054
13	161	Johnson & Johnson Pvt. Ltd.	9920277765, 022 66646464, 022 66718200, tenderspharma@its.jnj.com,R Asawale@ITS.JNJ.com	501, Arena Space, Behind Majas Bus Depot, Off. J.V. Link Road, Jogeshwari (East), Mumbai- 400060
14	161	Merck Specialities Private Limited	9899002707, 022 62109000, 022 62109999, 9899689294, nitesh.sharma@merckgroup.com,trendpro@merckgroup.com	Godrej One, 8th Floor, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai - 400079





### List of Approved Pharmaceutical firms of Rate Contract No. 161

15	161	MICRON PHARMACEUTICALS	8160376623, 0260 2405400/05/07/411/412, 0260 2405419, 9820081388, contactus@micronpharma.in, sales@micronpharma.in	PLOT NO 2117 A-2 PHASE III GIDC VAPI 396 195
16	161	MSD Pharmaceuticals Pvt. Ltd.	9810288687, 022-67898888, vivek.bhatia@merck.com, indpub@merck.com	229, 2nd Floor, Trade Centre Premises, Co. Op. Society Ltd. BKC, Bandra East, Mumbai-400051
17	161	MSN Laboratories Private Limited	7331135495, 040 30438716, 040 30438798, tenders@msnlabs.com	MSN House, Plot No. C-24, Industrial Estate, Sanathnagar, Hyderabad-500018, Telangana
18	161	Naprod Life Sciences Pvt. Ltd.	81006 44440, 022 4093 9000, institution@naprodgroup.com, abhijit.mukherjee@naprodgroup.com	304, Town Center, Andheri Kurla Road, Andheri East, Mumbai- 400059
19	161	Pfizer Limited	9771414156, '02266932000, '02226540274, GOVERNMENTTENDERSPFIZER@pfizer.com, Satendra.seth@pfizer.com, Rajesh.kadian2@pfizer.com	The Capital 1802/1901, Plot No C-70, G-Block, Bandra Kurla Complex, Bandra (E) Mumbai 400051
20	161	Pfizer Products India Private Limited	9771414156, '02266932000, '02226540274, governmenttendersppipl@pfizer.com, Satendra.seth@pfizer.com, Rajesh.kadian2@pfizer.com, vijay.pangle@pfizer.com	The Capital 1802/1901, Plot No C-70, G-Block, Bandra Kurla Complex, Bandra (E) Mumbai 400051
21	161	Primus Pharmaceuticals	9034004055, tenders@primuspharmaceutical.com, marketing@primuspharmaceutical.com	Primus Pharmaceuticals, Sadhoura Road, Mouza Ogli Khari, Vill. Asgarpur Majra, Distt. Sirmour, 173030, H.P

*[Handwritten signature]*



### List of Approved Pharmaceutical firms of Rate Contract No. 161

22	161	RIVPRA FORMULATION PVT. LTD	9818879555, 9311789536, (0120-4277177), tender@rivpraformulation.com, info@rivpraformulation.com	RIVPRA FORMULATION PVT. LTD. CORPORATE OFFICE: RADISSON BLU, KM TRADE TOWER, 11TH FLOOR, OFFICE NO: 1008, H-3, KAUSHAMBI, GHAZIABAD-201010 (U.P)
23	161	Roche Products (India) Pvt. Ltd	91 9769550543, 91 22 50457300, 91 22 50457301, rajenderan.krishnamurthy@roche.com, hemelin.karekar@roche.com	Roche Products (India) Pvt Ltd, 146-B, 166 A, Unit No. 7, 8, 9,8th Floor, R City Office, R City Mall Lal Bahadur Shastri Marg, Ghatkopar, Mumbai - 400 086
24	161	RPG Life Sciences Ltd	7738238787, 022 2 4981650 / 67555276(D), 022 2 4970127, smita.bhoir@rpgls.com	RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030
25	161	Samarth Life Sciences Pvt. Ltd.	8591082841, Tel No. - 022-2871 9322, 28719501, 2871 9510, 9967472793, samarth.tenders@samarthlife.com, rajive.shrivastava@samarthlife.com, samarth.tenders@samarthlife.com	Samarth Life Sciences Pvt. Ltd. Samarth House, 168, Bangur Nagar, Off Link Road, Near Ayappa Temple & Kallol Kali Temple Goregaon (West), Mumbai - 400 090 India
26	161	Sun Pharma Laboratories Limited	9820439962, 022 4324 4324, 022 4324 4343, Thomas.Edakalathoor@sunpharma.com	Sun House, 201 B/1, Western Express Highway, Goregaon East, Mumbai - 400063
27	161	Tablets (India) Limited	9600152152, 044 - 42050186, 044 - 28589090, hd@tabletsindia.com	# 72, Marshalls Road, "Jhaver Centre" R A Building, 4th Floor, Egmore, Chennai - 600 008
28	161	TROIKAA PHARMACEUTICALS LIMITED	9879615617, 079 26856242, 079 26856246, 7227069020, tenderorder@troikaapharma.com, institution@troikaapharma.com	TROIKAA HOUSE -1, SATYA MARG, BODAKDEV, AHMEDABAD - 380054





### List of Approved Pharmaceutical firms of Rate Contract No. 161

29	161	Virchow Biotech Pvt. Ltd.	8879110909, 022-28795635/022-28735609,022-28795699,9833197751, shambhu.s@virchowpharma.com,kiran.saxena@virchowpharma.com	Virchow Biotech Pvt. Ltd., 901, Dlh Park, S V Road, Goregaon West, Mumbai , Mumbai Suburban, Maharashtra, 400062
30	161	Wallace Pharmaceuticals Pvt. Ltd.	9820360019 / 9811129701, 022-68311100, 022-28390733, pravinwani@wallacepharma.net,institution@wallacepharma.net,pravinwani@wallacepharma.net,institution@wallacepharma.net,ms379@hotmail.com	Wallace Towers,5th Floor,139-140/B/1, Western Express Highway, Vile Parle(E),Mumbai-400057 Mktg Office: A 303/312 Floral Deck Plaza, Off Central MIDC Road, Andheri (East), Mumbai-400093
31	161	Zydus Lifesciences Limited	+91-63588 94556, '+91-079-71800000, 91-079-48040000 , '+91-079-71800192, '+91-91-98723 14125, NishuS.Dubey@zyduslife.com, chl_institution_business@zyduslife.com	Zydus Lifesciences Limited 4th Floor, "B" Wing, 'Zydus Corporate Park', Scheme No. 63, Survey No. 536,Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S.G.Highway, Ahmedabad - 382 481, Gujarat, India.

क.रा.बी.नि.  
ESIC



**Index RC- 161**

S.No.	RC No.	Item No.	Item Name and Description
1	161	287	Hydroxy Urea Tab/Cap- Each Tab/Cap to contain: Hydroxy Urea 500 mg
2	161	406	Azathioprine Tab/Cap- Each Tab/Cap to contain: Azathioprine 50 mg
3	161	490	Mycophenolate Mofetil Tab/Cap- Each Tab/Cap to contain: Mycophenolate Mofetil 500mg
4	161	600	Infliximab Inj- Each Vial to contain: Infliximab 100mg Packing: 1 Vial
5	161	1404	Docetaxel Inj- Each Vial to contain: Docetaxel 80mg Packing: 1 Vial
6	161	1448	Nimotuzumab Inj- Each Vial to contain: Nimotuzumab 50mg Packing:10 ml Vial
7	161	1456	CAPD Bag- Each bag to contain: CAPD Bag 7.5% Of Lcodextrin With Asymmetrical Y Connector Packing:2 Ltr Bag
8	161	1466	Each PFS to contain: Peg-Filgrastim 6mg Packing: 1 PFS
9	161	1477	Pemetrexed Disod. Inj- Each Vial to contain: Pemetrexed Disod. 500mg Packing: 1 Vial
10	161	1643	Sevelamer Tab/Cap- Each Tab to contain: Sevelamer 400mg
11	161	1647	Bevacizumab Inj- Each Vial to contain: Inj Bevacizumab 100mg Packing: 1 Vial
12	161	1648	Trastuzumab Inj- Each Vial to contain: Inj Trastuzumab 440mg Packing: 1 Vial
13	161	1708	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.03% Packing:10gm Tube





14	161	1709	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.1% Packing: 5gm to 10gm
15	161	1731	Rasburicase Inj- Each Vial to contain: Rasburicase 1.5 mg Packing: 1ml Vial
16	161	1736	Bicalutamide Tab/Cap- Each Tab/Cap to contain: Bicalutamide 50mg
17	161	1738	Sevelamer Tab/Cap- Each Tab/Cap to contain: Sevelamer 800mg
18	161	1804	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 1mg
19	161	1805	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 2mg
20	161	1809	Bortezomib Inj- Each Vial to contain: Bortezomib 3.5 mg Packing: 1 Vial
21	161	1814	Immunoglobulin- Each Inj to contain: Rho (D) Immune Globulin (Human) 1500 IU (300mcg) Packing: 1 Injection
22	161	1968	Valganociclovir Tab/Cap- Each Tab/Cap to contain: Valganociclovir 450mg
23	161	1969	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 180mg
24	161	1970	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 360mg
25	161	1972	Leuprolide Inj- Each PFS/Vial to contain: Leuprolide Acetate Depot 3.75mg Packing: 1 Vial/PFS
26	161	1982	Oxaliplatin Inj- Each Vial to contain: Oxaliplatin 50mg Packing: 1 Vial

8

भारत-बी.डी.  
E S I C

27	161	1983	Oxaliplatin Inj- Each Vial to contain: Oxaliplatin 100 Mg Packing: 1 Vial
28	161	1984	Paclitaxel Inj- Each Vial to contain: Paclitaxel 260mg Packing: 1 Vial
29	161	1988	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 0.5mg
30	161	1990	Sevelamer Sachet- Each Sachet to contain: Sevelamer Carbonate 800 mg
31	161	2117	Alectinib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Alectinib 150 mg Equivalent To Alectinib Hydrochloride 161.3 mg
32	161	2118	Atezolizumab Injection- Each 20ml Vial to contain: Atezolizumab Injection 1200mg Packing: 20ml Vial
33	161	2120	Tofacitinib Tab/Cap- Each Film Coated Tab/Cap to contain : Tofacitinib Citrate Equivalent to Tofacitinib 5mg
34	161	2128	Ibrutinib Tab/Cap- Each Cap/Tab to contain : Ibrutinib 140mg.
35	161	2133	Obinutuzumab Inj- Each Vial to contains: Obinutuzumab 1000 mg Packing: 1 Vial
36	161	2136	Pertuzumab Inj- Each 14ml Vial to contain: Pertuzumab 420mg (30mg/ml) Packing: 14ml Vial
37	161	2137	Triptorelin Pamoate Inj- Each Single Dose Vial Contains:(Sterile Lypholized) Triptorelin Pamoate Equivalent to Triptorelin 11.25mg Pamorelin La 11.25 Inj. Packing: 1 Vial
38	161	2138	Crizotinib Tab/Cap- Each Hard Geletin Tab/Cap to contain : Crizotinib 250mg





E S I C

39	161	2139	Denosumab Inj- Each Vial to contain: Denosumab 120 mg (70mg/ml) Total Fill 1.7ml in 5ml Vial Packing: 1 Vial
40	161	2140	Panitumumab Inj- Each Single Use Vial Of 5 ml to contain: Panitumumab 100 mg (20mg/ml) Packing: 5ml Vial
41	161	2143	Palbociclib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Palbociclib 125mg
42	161	2146	Paracetamol IV Inj- Each 50ml to contain Paracetamol IV 500mg Packing:50ml
43	161	2148	Irinotecan Inj- Each 5ml Vial to contain: Irinotecan 100 mg Packing: 5ml Vial
44	161	2149	Trastuzumab Inj- Each Vial to contain: Trastuzumab Emtansine 160mg Packing: 1 Vial
45	161	2156	Trastuzumab Inj- Each Vial to contain: Trastuzumab Emtansine 100mg Packing: 1 Vial
46	161	2159	Azacitidine Inj- Each Vial to contain: Azacitidine 100 mg Packing: 1 Vial
47	161	2170	Transtuzumab Inj- Each Vial to contain: Transtuzumab 150mg Packing: 1 Vial
48	161	2176	Irinotecan Inj- Each 2ml Vial to contains: Irinotecan 40 mg Packing: 2ml Vial
49	161	2179	Ramucirumab Concentrate For Solution For Infusion- Each Vial to contain: Ramucirumab 500mg / 50ml Vial Component :Ramucirumab 500mg,L-Histidine 32.5mg, L- Histidine Monohydrochloride 61.0mg, Glycine 499mg, Sodium Chloride 219mg, Polysorbate 80 5.0mg, Water For Injection Q.S Packing:50ml Vial



E S I C

50	161	2181	Golimumab (r-DNA Origin)- Each Single Use Pre-Filled Syringe to contain: Golimumab 50mg/0.5ml Component [Amount Per Dose (Mg)]: Golimumab (CNTO 148) -50mg, Sorbitol -20.5mg, L-Histidine -0.44mg, Polysorbate 80 - 0.075mg, Water For Injection - 0.5mg Packing: 1 PFS
51	161	2183	Heparin Topical Solution- Each ml to contain: Heparin Sodium IP 1000 IU, Absolute Alcohol IP 10% v/v Packing:5ml
52	161	2186	Snake Anti Venin (Polyvalent) IP 10ml (Enzyme Refined Equine Globulins)- Each 1ml Neutralises: 0.60mg Of Cobra Venom (Naja Naja), 0.45mg Of Common Krait Venom(Bungarus Caeruleus), 0.60mg Of Russell's Viper Venom (Vipera Russellii), 0.45mg Of Saw Scaled Viper Venom (Echis Carinatus) Packing:10ml vial/amp
53	161	2218	Daratumumab Inj- Each 5ml to contain: Daratumumab Concentrate For Solution For Infusion 100mg Packing: 5ml Vial
54	161	2219	Daratumumab Inj- Each 20ml to contain: Daratumumab Concentrate For Solution For Infusion 400mg Packing: 20ml Vial
55	161	2220	Pembrolizumab Inj- Each ml to contain: Pembrolizumab 25mg Packing:4ml Vial
56	161	2223	Mycophenolate Mofetil Powder- Each Bott to contain: Mycophenolate Mofetil Powder For Oral Suspension 1gm/5ml Packing:1 Bottle with 110gm powder for oral susp. Containing 35gm Mycophenolate Mofetil





ESIC

57	161	2225	Paclitaxel (Protein Bound Particales)- Each Inj to contain: Paclitaxel (Protein Bound Particales) For Injectable Suspension 100 Mg And This Is An Albumin-Bound Form Of Paclitaxel And This Is Presented As 100 Mg Of Paclitaxel In A Single Use 50 ml USP Type 1 Molded Glass Vial Individually Packaged In a Carton Packing:1 Injection
58	161	2227	Human Papillomavirus- Each 0.5ml to contain: Human Papillomavirus Quadrivalent (6, 11, 16 , 18 ) Vaccine, Recombinant Packing: 0.5ml Vial/Amp/PFS
59	161	2323	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 20mg Packing: 1 Vial/Amp
60	161	2324	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 120mg Packing: 1 Vial/Amp
61	161	2327	Alfa Ketoanalogue Tab/Cap- Each Tab/Cap to contain: Alpha Ketoanalogue 381mg, L- Histidine 38m, L-Lysine 105mg,L-Threonine 53mg, Tryptophan 23mg, Tyrosine 30mg
62	161	2329	Denosumab Inj- Each PFS to contain: Denosumab 60mg Packing: 1 PFS
63	161	2334	Anti Rabies Serum Equine Inj- Each ml to contain: Equine Antirabies Immunoglobulin 300 IU Packing: 5ml Vial
64	161	2336	Pneumococcal Vaccine- Each 0.5ml to contain: Pneumococcal Polysaccharide Conjugate Vaccine (13 Valent) Packing: 1 PFS
65	161	2500	Amivantamab Injection-Each ml to contain:Amivantamab 50mg Packing:7ml Vial
66	161	2501	Antithymocyte Immunoglobulin Inj. -Each ml to contains:Antithymocyte Immunoglobulin (Equine)-50mg, Packing:5ml vial



ESIC

67	161	2502	Avelumab Inj.-Each ml to contain Avelumab 20mg Packing:10ml vial
68	161	2504	Lorlatinib Tablet-Each Tab to contain: Lorlatinib 100mg
69	161	1339a	Human Tetanus Specific Immunoglobulin- Each Vial to contain: Human Tetanus Specific Immunoglobulin 250 Units. Packing:1 Vial
70	161	1339b	Human Tetanus Specific Immunoglobulin- Each Vial to contain: Human Tetanus Specific Immunoglobulin 500 Units. Packing: 1 Vial
71	161	1454b	Capecitabine Tab/Cap- Each Tab/Cap to contain: Capecitabine 500mg
72	161	1473a	Sunitinib Malate Tab/Cap- Each Tab/Cap to contain: Sunitinib Malate 12.5mg
73	161	1476b	Deferasirox Tab/Cap- Each Tab/Cap to contain Deferasirox 400mg
74	161	1650a	Filgrastim Inj- Each PFS/Vial to contain: Filgrastim 150 mcg Packing: 1 Vial/PFS
75	161	459b	Gemcitabine Inj- Each Vial to contain: Gemcitabine 1gm Packing: 1 Vial
76	161	487a	Paclitaxel Inj- Each Vial to contain: Paclitaxel 100mg Packing: 1 Vial
77	161	488a	Carboplatin Inj- Each Vial to contain: Carboplatin 150mg Packing: 1 Vial
78	161	488b	Carboplatin Inj- Each Vial to contain: Carboplatin 450mg Packing:1 Vial
79	161	578b	Alendronate Tab/Cap- Each Tab/Cap to contain: Alendronate 70mg



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Cipla Ltd.	287	Hydroxy Urea Tab/Cap- Each Tab/Cap to contain: Hydroxy Urea 500 mg	1 Tab/Cap	CYTODROX	10 Caps	2.98/ 1 Tab/Cap	Rupees Two Paise NinetyEight Only	L1
161	RPG Life Sciences Ltd	406	Azathioprine Tab/Cap- Each Tab/Cap to contain: Azathioprine 50 mg	1 Tab/Cap	Azoran 50mg	20 tab	0.96/ 1 Tab/Cap	Paise NinetySix Only	L1
161	Zydus Lifesciences Limited	406	Azathioprine Tab/Cap- Each Tab/Cap to contain: Azathioprine 50 mg	1 Tab/Cap	Zymurine	10 Tablets	1.05/ 1 Tab/Cap	Rupee One Paise Five Only	L2
161	Bajaj Healthcare Limited	406	Azathioprine Tab/Cap- Each Tab/Cap to contain: Azathioprine 50 mg	1 Tab/Cap	PRINJAJ 50	10 Tabs	1.22/ 1 Tab/Cap	Rupee One Paise TwentyTwo Only	L3
161	RPG Life Sciences Ltd	490	Mycophenolate Mofetil Tab/Cap- Each Tab/Cap to contain: Mycophenolate Mofetil 500mg	1 Tab/Cap	Mofetyl 500mg	10 tab	6.82/ 1 Tab/Cap	Rupees Six Paise EightyTwo Only	L1
161	Concord Biotech Limited	490	Mycophenolate Mofetil Tab/Cap- Each Tab/Cap to contain: Mycophenolate Mofetil 500mg	1 Tab/Cap	Mofecon 500	10 Tabs	6.95/ 1 Tab/Cap	Rupees Six Paise NinetyFive Only	L2
161	RIVPRA FORMULATION PVT. LTD,	490	Mycophenolate Mofetil Tab/Cap- Each Tab/Cap to contain: Mycophenolate Mofetil 500mg	1 Tab/Cap	Same as in Item	10 Tabs	7.30/ 1 Tab/Cap	Rupees Seven Paise Thirty Only	L3

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Johnson & Johnson Pvt. Ltd.	600	Infliximab Inj- Each Vial to contain: Infliximab 100mg Packing: 1 Vial	1 Vial	Remicade® Mfg. By: M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	1 Vial	14158.11/ 1 Vial	Rupees Fourteen Thousand One Hundred FiftyEight Paise Eleven Only	L1
161	Samarth Life Sciences Pvt. Ltd.	1404	Docetaxel Inj- Each Vial to contain: Docetaxel 80mg Packing: 1 Vial	1 Vial	DOCET	1 VIAL	296.10/ 1 Vial	Rupees Two Hundred NinetySix Paise Ten Only	L1
161	Intas Pharmaceuticals Ltd	1404	Docetaxel Inj- Each Vial to contain: Docetaxel 80mg Packing: 1 Vial	1 Vial	TAXOCARE 80	4 ml Vial	529.00/ 1 Vial	Rupees Five Hundred TwentyNine Only	L2
161	Getwell Pharma India Private Limited	1404	Docetaxel Inj- Each Vial to contain: Docetaxel 80mg Packing: 1 Vial	1 Vial	Taxewell	1 Vial	747.00/ 1 Vial	Rupees Seven Hundred FortySeven Only	L3
161	Biocon Biologics Limited	1448	Nimotuzumab Inj- Each Vial to contain: Nimotuzumab 50mg Packing: 10 ml Vial	1 Vial	BIOMAB EGFR	1 VIAL of 10 ml	11027.75/ 1 Vial	Rupees Eleven Thousand TwentySeven Paise SeventyFive Only	L1
161	Baxter India Pvt Ltd	1456	CAPD Bag- Each bag to contain: CAPD Bag 7.5% Of Lcodextrin With Asymmetrical Y Connector Packing: 2 Ltr Bag	1 Bag	Extraneal 7.5% Mfg. By: M/s Baxter Healthcare SA, Singapore	1 Bag of 2000ml	747.40/ 1 Bag	Rupees Seven Hundred FourtySeven Paise Fourty Only	L1

*Sagar*  
उप निदेशक आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Zydus Lifesciences Limited	1466	Each PFS to contain: Peg-Filgrastim 6mg Packing: 1 PFS	1 PFS	Pegstim	1 PFS	950.00/ 1 PFS	Rupees Nine Hundred Fifty Only	L1
161	Intas Pharmaceuticals Ltd	1466	Each PFS to contain: Peg-Filgrastim 6mg Packing: 1 PFS	1 PFS	PEGASTA	0.6 ml PFS	1395.00/ 1 PFS	Rupees One Thousand Three Hundred NinetyFive Only	L2
161	Naprod Life Sciences Pvt. Ltd.	1477	Pemetrexed Disod. Inj- Each Vial to contain: Pemetrexed Disod. 500mg Packing: 1 Vial	1 Vial	Same as in Item	1 Vial	1295.00/ 1 Vial	Rupees One Thousand Two Hundred NinetyFive Only	L1
161	Getwell Pharma India Private Limited	1477	Pemetrexed Disod. Inj- Each Vial to contain: Pemetrexed Disod. 500mg Packing: 1 Vial	1 Vial	Pemetra	1 Vial	2247.00/ 1 Vial	Rupees Two Thousand Two Hundred FourtySeven Only	L2
161	Biodeal Pharmaceuticals Ltd.	1643	Sevelamer Tab/Cap- Each Tab to contain: Sevelamer 400mg	1 Tab/Cap	Same as in Item	10 Tabs	2.43/ 1 Tab/Cap	Rupees Two Paise FortyThree Only	L1
161	Intas Pharmaceuticals Ltd	1643	Sevelamer Tab/Cap- Each Tab to contain: Sevelamer 400mg	1 Tab/Cap	ACUTROL 400	15 Tab	3.53/ 1 Tab/Cap	Rupees Three Paise FiftyThree Only	L2
161	RIVPRA FORMULATION PVT. LTD,	1643	Sevelamer Tab/Cap- Each Tab to contain: Sevelamer 400mg	1 Tab/Cap	Same as in Item	10 Tabs	4.35/ 1 Tab/Cap	Rupees Four Paise ThirtyFive Only	L3

  
 Deputy Medical Commissioner (AR.SI./PI.SI.)  
 Deputy Medical Commissioner (RC/PC)

27

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Dr. Reddy's Laboratories Limited	1647	Bevacizumab Inj- Each Vial to contain: Inj Bevacizumab 100mg Packing: 1 Vial	1 Vial	Versavo 100	1 Vial	1399.00/ 1 Vial	Rupees One Thousand Three Hundred NinetyNine Only	L1
161	Intas Pharmaceuticals Ltd	1647	Bevacizumab Inj- Each Vial to contain: Inj Bevacizumab 100mg Packing: 1 Vial	1 Vial	BEVATAS 100	4 ml Vial	1654.00/ 1 Vial	Rupees One Thousand Six Hundred FiftyFour Only	L2
161	Zydus Lifesciences Limited	1647	Bevacizumab Inj- Each Vial to contain: Inj Bevacizumab 100mg Packing: 1 Vial	1 Vial	Bryxta 100	1 Vial	2105.00/ 1 Vial	Rupees Two Thousand One Hundred Five Only	L3
161	Zydus Lifesciences Limited	1648	Trastuzumab Inj- Each Vial to contain: Inj Trastuzumab 440mg Packing: 1 Vial	1 Vial	Vivitra	1 Vial	6080.00/ 1 Vial	Rupees Six Thousand Eighty Only	L1
161	Intas Pharmaceuticals Ltd	1648	Trastuzumab Inj- Each Vial to contain: Inj Trastuzumab 440mg Packing: 1 Vial	1 Vial	ELEFTHA	1 Vial	6198.00/ 1 Vial	Rupees Six Thousand One Hundred NinetyEight Only	L2
161	MICRON PHARMACEUTICALS	1708	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.03% Packing:10gm Tube	1gm	Same as in Item	10 gm Tube	2.70/1gm	Rupees Two Paise Seventy Only	L1
161	RIVPRA FORMULATION PVT. LTD,	1708	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.03% Packing:10gm Tube	1gm	Same as in Item	10 GM TUBE	2.80/1gm	Rupees Two Paise Eighty Only	L2

  
 Deputy Medical Commissioner (RC/PC)

28



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Wallace Pharmaceuticals Pvt. Ltd.	1708	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.03% Packing:10gm Tube	1gm	T-TOP	10gm Tube	3.30/1gm	Rupees Three Paise Thirty Only	L3
161	Biodeal Pharmaceuticals Ltd.	1709	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.1% Packing: 5gm to 10gm	1 gm	Same as in Item	10GM TUBE	3.34/ 1 gm	Rupees Three Paise ThirtyFour Only	L1
161	MICRON PHARMACEUTICAL S	1709	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.1% Packing: 5gm to 10gm	1 gm	Same as in Item	10 gm Tube	4.50/ 1 gm	Rupees Four Paise Fifty Only	L2
161	RIVPRA FORMULATION PVT. LTD,	1709	Tacrolimus Oint- Each Tube to contain: Tacrolimus 0.1% Packing: 5gm to 10gm	1 gm	TACRORIV	10 GM TUBE	6.50/ 1 gm	Rupees Six Paise Fifty Only	L3
161	Virchow Biotech Pvt. Ltd.	1731	Rasburicase Inj- Each Vial to contain: Rasburicase 1.5 mg Packing:1ml Vial	1 Vial	Tuly	1 Vial	5830.00/ 1 Vial	Rupees Five Thousand Eight Hundred Thirty Only	L1
161	Intas Pharmaceuticals Ltd	1736	Bicalutamide Tab/Cap- Each Tab/Cap to contain: Bicalutamide 50mg	1 Tab/Cap	BICAL-50	10 Tab	5.70/ 1 Tab/Cap	Rupees Five Paise Seventy Only	L1

*Sanyal*  
उप चिकित्सा अधिकारी (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Samarth Life Sciences Pvt. Ltd.	1736	Bicalutamide Tab/Cap- Each Tab/Cap to contain: Bicalutamide 50mg	1 Tab/Cap	CALUDEEC	10 TABS	6.75/ 1 Tab/Cap	Rupees Six Paise SeventyFive Only	L2
161	Primus Pharmaceuticals	1738	Sevelamer Tab/Cap- Each Tab/Cap to contain: Sevelamer 800mg	1 Tab/Cap	Velamar-800	10 Tabs	7.49/ 1 Tab/Cap	Rupees Seven Paise FourtyNine Only	L1
161	RIVPRA FORMULATION PVT. LTD,	1738	Sevelamer Tab/Cap- Each Tab/Cap to contain: Sevelamer 800mg	1 Tab/Cap	PHOSRIK-800	10 Tabs	8.25/ 1 Tab/Cap	Rupees Eight Paise TwentyFive Only	L2
161	Sun Pharma Laboratories Limited	1738	Sevelamer Tab/Cap- Each Tab/Cap to contain: Sevelamer 800mg	1 Tab/Cap	REVLAMER 800	10 Tabs	12.68/ 1 Tab/Cap	Rupees Twelve Paise SixtyEight Only	L3
161	Concord Biotech Limited	1804	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 1mg	1 Tab/Cap	Tacrocord 1	10 Caps	4.55/ 1 Tab/Cap	Rupees Four Paise FiftyFive Only	L1
161	RIVPRA FORMULATION PVT. LTD,	1804	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 1mg	1 Tab/Cap	TACRORIV-1	10 Caps	4.60/ 1 Tab/Cap	Rupees Four Paise Sixty Only	L2
161	Intas Pharmaceuticals Ltd	1804	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 1mg	1 Tab/Cap	TAKFA 1	10 Cap	5.90/ 1 Tab/Cap	Rupees Five Paise Ninety Only	L3

*Singh*  
 Deputy Medical Commissioner (RC/PC)



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	RIVPRA FORMULATION PVT. LTD,	1805	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 2mg	1 Tab/Cap	TACRORIV-2	10 Caps	8.80/ 1 Tab/Cap	Rupees Eight Paise Eighty Only	L1
161	Concord Biotech Limited	1805	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 2mg	1 Tab/Cap	Tacrocord 2	10 Caps	9.05/ 1 Tab/Cap	Rupees Nine Paise Five Only	L2
161	Zydus Lifesciences Limited	1805	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 2mg	1 Tab/Cap	Tacromus 2	10 Capsules	21.00/ 1 Tab/Cap	Rupees TwentyOne Only	L3
161	Naprod Life Sciences Pvt. Ltd.	1809	Bortezomib Inj- Each Vial to contain: Bortezomib 3.5 mg Packing: 1 Vial	1 Vial	M-Prib-3.5	1 Vial	1260.00/ 1 Vial	Rupees One Thousand Two Hundred Sixty Only	L1
161	Getwell Pharma India Private Limited	1809	Bortezomib Inj- Each Vial to contain: Bortezomib 3.5 mg Packing: 1 Vial	1 Vial	Neomib	1 Vial	3500.00/ 1 Vial	Rupees Three Thousand Five Hundred Only	L2
161	Bharat Serums And Vaccines Limited	1814	Immunoglobulin- Each Inj to contain: Rho (D) Immune Globulin (Human) 1500 IU (300mcg) Packing: 1 Injection	1 inj	ANTI D	1 Vial of 300mcg	2388.00/ 1 vial	Rupees Two Thousand Three Hundred EightyEight Only	L1

ESIC

*Sayan*  
उप विभागाध्यक्ष (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

31

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	RIVPRA FORMULATION PVT. LTD,	1968	Valganociclovir Tab/Cap- Each Tab/Cap to contain: Valganociclovir 450mg	1 Tab/Cap	VALGARIV-450	10 Tabs	87.00/ 1 Tab/Cap	Rupees EightySeven Only	L1
161	Zydus Lifesciences Limited	1968	Valganociclovir Tab/Cap- Each Tab/Cap to contain: Valganociclovir 450mg	1 Tab/Cap	Virofi	10 Tablets	104.00/ 1 Tab/Cap	Rupees One Hundred Four Only	L2
161	Intas Pharmaceuticals Ltd	1969	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 180mg	1 Tab/Cap	MYCOFIT-S 180	10 Tab	5.40/ 1 Tab/Cap	Rupees Five Paise Fourty Only	L1
161	RIVPRA FORMULATION PVT. LTD,	1969	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 180mg	1 Tab/Cap	MYCORIK-S 180	10 Tabs	7.25/ 1 Tab/Cap	Rupees Seven Paise TwentyFive Only	L2
161	Concord Biotech Limited	1969	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 180mg	1 Tab/Cap	Mofecon S 180	10 Tabs	10.95/ 1 Tab/Cap	Rupees Ten Paise NinetyFive Only	L3
161	Concord Biotech Limited	1970	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 360mg	1 Tab/Cap	Mofecon S 360	10 Tabs	6.95/ 1 Tab/Cap	Rupees Six Paise NinetyFive Only	L1



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	RPG Life Sciences Ltd	1970	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 360mg	1 Tab/Cap	Mofetyl S 360mg	10 tab	7.27/ 1 Tab/Cap	Rupees Seven Paise TwentySeven Only	L2
161	RIVPRA FORMULATION PVT. LTD,	1970	Mycophenolate Tab/Cap- Each Tab/Cap to contain: Mycophenolic Acid (As Sodium Salt) 360mg	1 Tab/Cap	Same as in Item	10 Tabs	7.80/ 1 Tab/Cap	Rupees Seven Paise Eighty Only	L3
161	Bharat Serums And Vaccines Limited	1972	Leuprolide Inj- Each PFS/Vial to contain: Leuprolide Acetate Depot 3.75mg Packing: 1 Vial/PFS	1 PFS/Vial	LUPRODEX 3.75MG	1 Vial of 3.75mg	1490.00/ 1 PFS/Vial	Rupees One Thousand Four Hundred Ninety Only	L1
161	Getwell Pharma India Private Limited	1982	Oxaliplatin Inj- Each Vial to contain: Oxaliplatin 50mg Packing: 1 Vial	1 Vial	Xylotin 50mg/25ml	1 Vial	1648.00/ 1 Vial	Rupees One Thousand Six Hundred FourtyEight Only	L1
161	Naprod Life Sciences Pvt. Ltd.	1983	Oxaliplatin Inj- Each Vial to contain: Oxaliplatin 100 Mg Packing: 1 Vial	1 Vial	Zildox-100	1 Vial	918.00/ 1 Vial	Rupees Nine Hundred Eighteen Only	L1
161	Getwell Pharma India Private Limited	1983	Oxaliplatin Inj- Each Vial to contain: Oxaliplatin 100 Mg Packing: 1 Vial	1 Vial	Xylotin 100mg/50ml	1 Vial	3349.00/ 1 Vial	Rupees Three Thousand Three Hundred FourtyNine Only	L2

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Getwell Pharma India Private Limited	1984	Paclitaxel Inj- Each Vial to contain: Paclitaxel 260mg Packing: 1 Vial	1 Vial	Pacliwel 260mg/43.4ml	1 Vial	625.00/ 1 Vial	Rupees Six Hundred TwentyFive Only	L1
161	Naprod Life Sciences Pvt. Ltd.	1984	Paclitaxel Inj- Each Vial to contain: Paclitaxel 260mg Packing: 1 Vial	1 Vial	Same as in Item	1 Vial	665.00/ 1 Vial	Rupees Six Hundred SixtyFive Only	L2
161	RIVPRA FORMULATION PVT. LTD,	1988	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 0.5mg	1 Tab/Cap	TACRORIV-0.5	10 Caps	3.55/ 1 Tab/Cap	Rupees Three Paise FiftyFive Only	L1
161	Concord Biotech Limited	1988	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 0.5mg	1 Tab/Cap	Tacrocord 0.50	10 Caps	3.65/ 1 Tab/Cap	Rupees Three Paise SixtyFive Only	L2
161	Zydus Lifesciences Limited	1988	Tacrolimus Tab/Cap- Each Tab/Cap to contain: Tacrolimus 0.5mg	1 Tab/Cap	Tacromus 0.5	10 Capsules	3.95/ 1 Tab/Cap	Rupees Three Paise NinetyFive Only	L3
161	RIVPRA FORMULATION PVT. LTD,	1990	Sevelamer Sachet- Each Sachet to contain: Sevelamer Carbonate 800 mg	1 Sachet	PHOSRIK-800	1 Sachet	29.20/ 1 Sachet	Rupees TwentyNine Paise Twenty Only	L1

क.स.बी.नि.  
ESIC

*Sanyal*  
उप निदेशिका आयुक्त (अ.स.ी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Roche Products (India) Pvt. Ltd	2117	Alectinib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Alectinib 150 mg Equivalent To Alectinib Hydrochloride 161.3 mg	1 Tab/Cap	Alecensa 150 mg Mfg. By: F. Hoffmann-La Roche Ltd, Switzerland at M/s EXCELLA GmbH & Co. KG, Feucht, Germany	(4 packs x 7 blisters x 8 capsule)	1674.11/ 1 Tab/Cap	Rupees One Thousand Six Hundred SeventyFour Paise Eleven Only	L1
161	Roche Products (India) Pvt. Ltd	2118	Atezolizumab Injection- Each 20ml Vial to contain: Atezolizumab Injection 1200mg Packing: 20ml Vial	1 Vial	Tecentriq 1200mg Mfg. By: F. Hoffmann-La Roche Ltd at Roche Diagnostics GmbH, SandhoferStrasse, 116, D-68305, Mannheim, Germany	1 Vial	276000.00/ 1 Vial	Rupees Two Lakh SeventySix Thousand Only	L1
161	MSN Laboratories Private Limited	2120	Tofacitinib Tab/Cap- Each Film Coated Tab/Cap to contain : Tofacitinib Citrate Equivalent to Tofacitinib 5mg	1 Tab/Cap	Tofadoz 5	10 Tabs	6.90/ 1 Tab/Cap	Rupees Six Paise Ninety Only	L1
161	Intas Pharmaceuticals Ltd	2120	Tofacitinib Tab/Cap- Each Film Coated Tab/Cap to contain : Tofacitinib Citrate Equivalent to Tofacitinib 5mg	1 Tab/Cap	TOFATAS	14 Tab	7.90/ 1 Tab/Cap	Rupees Seven Paise Ninety Only	L2
161	Wallace Pharmaceuticals Pvt. Ltd.	2120	Tofacitinib Tab/Cap- Each Film Coated Tab/Cap to contain : Tofacitinib Citrate Equivalent to Tofacitinib 5mg	1 Tab/Cap	TOFZA	14 Tabs	8.90/ 1 Tab/Cap	Rupees Eight Paise Ninety Only	L3

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Johnson & Johnson Pvt. Ltd.	2128	Ibrutinib Tab/Cap- Each Cap/Tab to contain : Ibrutinib 140mg.	1 Tab/Cap	Imbruvica® Mfg. By: M/s. Cilag AG, , Hochstrasse 201, - Schaffhausen Schaffhausen(Switz erland) - CH-8200.	Bottle of 90 Capsule	1557.39/ 1 Tab/Cap	Rupees One Thousand Five Hundred FiftySeven Paise ThirtyNine Only	L1
161	Roche Products (India) Pvt. Ltd	2133	Obinutuzumab Inj- Each Vial to contains: Obinutuzumab 1000 mg Packing: 1 Vial	1 Vial	Gazyva 1000mg Mfg. By: F. Hoffmann-La Roche Ltd at Roche Diagnostics GmbH, SandhoferStrasse, 116, D-68305, Mannheim, Germany	1 Vial	256021.00/ 1 Vial	Rupees Two Lakh FiftySix Thousand TwentyOne Only	L1
161	Roche Products (India) Pvt. Ltd	2136	Pertuzumab Inj- Each 14ml Vial to contain: Pertuzumab 420mg (30mg/ml) Packing: 14ml Vial	1 Vial	Perjeta 420mg Mfg. By: F. Hoffmann-La Roche Ltd at Roche Diagnostics GmbH, SandhoferStrasse, 116, D-68305, Mannheim, Germany	1 Vial	169330.00/ 1 Vial	Rupees One Lakh SixtyNine Thousand Three Hundred Thirty Only	L1

ESIC

*Sayer*  
उप निदेशक आयुर्विज्ञान (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Dr. Reddy's Laboratories Limited	2137	Triptorelin Pamoate Inj- Each Single Dose Vial Contains:(Sterile Lypholized) Triptorelin Pamoate Equivalent to Triptorelin 11.25mg Pamorelin La 11.25 Inj. Packing: 1 Vial	1 Vial	Pamorelin LA 11.25 Mfg. By: Debiopharm Research & Manufacturing SA, Switzerland	1 Vial	10850.00/ 1 Vial	Rupees Ten Thousand Eight Hundred Fifty Only	L1
161	Pfizer Products India Private Limited	2138	Crizotinib Tab/Cap- Each Hard Geletin Tab/Cap to contain : Crizotinib 250mg	1 Tab/Cap	CRIZALK Mfg. By: M/s Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg, Mooswaldallee 1,Freiburg NA (Germany) -79090	10 Capsules	1160.50/ 1 Tab/Cap	Rupees One Thousand One Hundred Sixty Paise Fifty Only	L1
161	Intas Pharmaceuticals Ltd	2139	Denosumab Inj- Each Vial to contain: Denosumab 120 mg (70mg/ml) Total Fill 1.7ml in 5ml Vial Packing: 1 Vial	1 Vial	ESENTRA 120	1 Vial	10349.00/ 1 Vial	Rupees Ten Thousand Three Hundred FourtyNine Only	L1
161	Dr. Reddy's Laboratories Limited	2140	Panitumumab Inj- Each Single Use Vial Of 5 ml to contain: Panitumumab 100 mg (20mg/ml) Packing: 5ml Vial	1 Vial	Vectibix Mfg. By: Amgen Manufacturing Limited (AML), USA	1 Vial	27063.00/ 1 Vial	Rupees TwentySeven Thousand SixtyThree Only	L1

  
उप विक्लि आरु (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

37

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	MSN Laboratories Private Limited	2143	Palbociclib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Palbociclib 125mg	1 Tab/Cap	Palborest 125	7 Tabs	52.53/ 1 Tab/Cap	Rupees FiftyTwo Paise FiftyThree Only	L1
161	Zydus Lifesciences Limited	2143	Palbociclib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Palbociclib 125mg	1 Tab/Cap	Kixta 125	7 Capsules	77.62/ 1 Tab/Cap	Rupees SeventySeven Paise SixtyTwo Only	L2
161	Cipla Ltd.	2143	Palbociclib Tab/Cap- Each Hard Gelatin Tab/Cap to contain: Palbociclib 125mg	1 Tab/Cap	Piclib 125	3x7's count HDPE Bottle	98.00/ 1 Tab/Cap	Rupees NinetyEight Only	L3
161	Tablets (India) Limited	2146	Paracetamol IV Inj- Each 50ml to contain Paracetamol IV 500mg Packing:50ml	1ml	Fevastin IV 50ml	50ml Glass Bottle	1.57/1ml	Rupee One Paise FiftySeven Only	L1
161	Fresenius Kabi India Private Limited	2146	Paracetamol IV Inj- Each 50ml to contain Paracetamol IV 500mg Packing:50ml	1ml	Kabimol	50ml Glass Bottle	1.84/1ml	Rupee One Paise EightyFour Only	L2
161	Naprod Life Sciences Pvt. Ltd.	2148	Irinotecan Inj- Each 5ml Vial to contain: Irinotecan 100 mg Packing: 5ml Vial	1 Vial	Same as in Item	1 Vial	425.00/ 1 Vial	Rupees Four Hundred TwentyFive Only	L1

क.स.बी.नि.  
ESIC

*Sangh*  
रम चिकित्सा आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Getwell Pharma India Private Limited	2148	Irinotecan Inj- Each 5ml Vial to contain: Irinotecan 100 mg Packing: 5ml Vial	1 Vial	Rinowel 100mg/5ml	1 Vial	1069.71/ 1 Vial	Rupees One Thousand SixtyNine Paise SeventyOne Only	L2
161	Zydus Lifesciences Limited	2149	Trastuzumab Inj- Each Vial to contain: Trastuzumab Emtansine 160mg Packing: 1 Vial	1 Vial	Ujvira	1 Vial	37198.64/ 1 Vial	Rupees ThirtySeven Thousand One Hundred NinetyEight Paise SixtyFour Only	L1
161	Roche Products (India) Pvt. Ltd	2149	Trastuzumab Inj- Each Vial to contain: Trastuzumab Emtansine 160mg Packing: 1 Vial	1 Vial	Kadcyla 160mg Mfg. By: F. Hoffmann-La Roche Ltd, Wurmisweg, CH- 4303, Kaiseraugst, Switzerland.	1 Vial	169080.00/ 1 Vial	Rupees One Lakh SixtyNine Thousand Eighty Only	L2
161	Zydus Lifesciences Limited	2156	Trastuzumab Inj- Each Vial to contain: Trastuzumab Emtansine 100mg Packing: 1 Vial	1 Vial	Ujvira	1 Vial	24177.83/ 1 Vial	Rupees TwentyFour Thousand One Hundred SeventySeven Paise EightyThree Only	L1
161	Roche Products (India) Pvt. Ltd	2156	Trastuzumab Inj- Each Vial to contain: Trastuzumab Emtansine 100mg Packing: 1 Vial	1 Vial	Kadcyla 100mg Mfg. By: F. Hoffmann-La Roche Ltd, Wurmisweg, CH- 4303, Kaiseraugst, Switzerland.	1 Vial	105680.00/ 1 Vial	Rupees One Lakh Five Thousand Six Hundred Eighty Only	L2

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Getwell Pharma India Private Limited	2159	Azacidine Inj- Each Vial to contain: Azacidine 100 mg Packing: 1 Vial	1 Vial	Azacite 100mg	1 Vial	3334.76/ 1 Vial	Rupees Three Thousand Three Hundred ThirtyFour Paise SeventySix Only	L1
161	Zydus Lifesciences Limited	2170	Transtuzumab Inj- Each Vial to contain: Transtuzumab 150mg Packing: 1 Vial	1 Vial	Vivitra	1 Vial	2080.00/ 1 Vial	Rupees Two Thousand Eighty Only	L1
161	Naprod Life Sciences Pvt. Ltd.	2176	Irinotecan Inj- Each 2ml Vial to contains: Irinotecan 40 mg Packing: 2ml Vial	1 Vial	Torsirin 40mg/2ml	1 Vial	205.00/ 1 Vial	Rupees Two Hundred Five Only	L1
161	Getwell Pharma India Private Limited	2176	Irinotecan Inj- Each 2ml Vial to contains: Irinotecan 40 mg Packing: 2ml Vial	1 Vial	Rinowel 40mg/2ml	1 Vial	639.11/ 1 Vial	Rupees Six Hundred ThirtyNine Paise Eleven Only	L2
161	Eli Lilly and Company (India) Pvt. Ltd.	2179	Ramucirumab Concentrate For Solution For Infusion- Each Vial to contain: Ramucirumab 500mg / 50ml Vial Component ;Ramucirumab 500mg,L-Histidine 32.5mg, L- Histidine Monohydrochloride 61.0mg, Glycine 499mg, Sodium Chloride 219mg, Polysorbate 80 5.0mg, Water For Injection Q.S Packing:50ml Vial	1 Vial	CYRAMZA Mfg. By: Lilly S.A., Avda. de la Industria, 30- 28108, Alcobendas, Madrid, Spain	1 VIAL	125400.00/ 1 Vial	Rupees One Lakh TwentyFive Thousand Four Hundred Only	L1

*[Signature]*  
 सप चिकित्सा अधिकारी (आर.सी./पी.सी.)  
 Deputy Medical Commissioner (RC/PC)



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Johnson & Johnson Pvt. Ltd.	2181	Golimumab (r-DNA Origin)- Each Single Use Pre-Filled Syringe to contain: Golimumab 50mg/0.5ml Component [Amount Per Dose (Mg)]: Golimumab (CNTO 148) - 50mg, Sorbitol -20.5mg, L-Histidine -0.44mg, Polysorbate 80 - 0.075mg, Water For Injection - 0.5mg Packing: 1 PFS	1 PFS	Simponi® 50 mg Mfg. By: M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH-8200	Pre-Filled Syringe in Autoinjector (SmartJect)	19561.50/ 1 PFS	Rupees Nineteen Thousand Five Hundred SixtyOne Paise Fifty Only	L1
161	TROIKAA PHARMACEUTICALS LIMITED	2183	Heparin Topical Solution- Each ml to contain: Heparin Sodium IP 1000 IU, Absolute Alcohol IP 10% v/v Packing:5ml	5 ml vial	PHLEBOTROY QPS	5ML pack	115.00/ 5 ml vial	Rupees One Hundred Fifteen Only	L1
161	Bharat Serums And Vaccines Limited	2186	Snake Anti Venin (Polyvalent) IP 10ml (Enzyme Refined Equine Globulins)- Each 1ml Neutralises: 0.60mg Of Cobra Venom (Naja Naja), 0.45mg Of Common Krait Venom(Bungarus Caeruleus), 0.60mg Of Ruseells Viper Venom (Vipera Russellii), 0.45mg Of Saw Scaled Viper Venom (Echis Carinatus) Packing:10ml vial/amp	1 Vial/Amp	SNAKE VENOM ANTISERUM I.P LYOPHILIZED	Vial of 10ml	540.00/ 1 Vial	Rupees Five Hundred Fourty Only	L1

क.रा.बी.नि.  
ESIC

  
उप-चिकित्सा अधिकारी (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

41

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Johnson & Johnson Pvt. Ltd.	2218	Daratumumab Inj- Each 5ml to contain: Daratumumab Concentrate For Solution For Infusion 100mg Packing: 5ml Vial	1 Vial	Darzalex® 100 mg Mfg. By: M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH- 8200	1 Vial	13001.00/ 1 Vial	Rupees Thirteen Thousand One Only	L1
161	Johnson & Johnson Pvt. Ltd.	2219	Daratumumab Inj- Each 20ml to contain: Daratumumab Concentrate For Solution For Infusion 400mg Packing: 20ml Vial	1 Vial	Darzalex® 400 mg Mfg. By: M/s. Cilag AG, , Hochstrasse 201, Schaffhausen (Switzerland) - CH- 8200	1 Vial	51900.00/ 1 Vial	Rupees FiftyOne Thousand Nine Hundred Only	L1
161	MSD Pharmaceuticals Pvt. Ltd.	2220	Pembrolizumab Inj- Each ml to contain: Pembrolizumab 25mg Packing:4ml Vial	1 Vial	Keytruda Mfg. By: Merck Sharp and Dohme B.V., Waarderweg 39, Harleem, 2031 BN, Netherlands	4ml Vial	172800.00/ 1 Vial	Rupees One Lakh SeventyTwo Thousand Eight Hundred Only	L1
161	Concord Biotech Limited	2223	Mycophenolate Mofetil Powder- Each Bott to contain: Mycophenolate Mofetil Powder For Oral Suspension 1gm/5ml Packing:1 Bottle with 110gm powder for oral susp. Containing 35gm Mycophenolate Mofetil	1 Bottle	Mofecon OS	1 Bottle	5990.00/ 1 Bottle	Rupees Five Thousand Nine Hundred Ninety Only	L1

*Saini*  
उप विहित आर.सी./पी.सी.  
Deputy Medical Commissioner (RC/PC)

42



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Getwell Pharma India Private Limited	2225	Paclitaxel (Protein Bound Particales)- Each Inj to contain: Paclitaxel (Protein Bound Particales) For Injectable Suspension 100 Mg And This Is An Albumin-Bound Form Of Paclitaxel And This Is Presented As 100 Mg Of Paclitaxel In A Single Use 50 ml USP Type 1 Molded Glass Vial Individually Packaged In a Carton Packing:1 Injection	1 Vial	Nanopac 100mg	1 Vial	2584.00/ 1 Vial	Rupees Two Thousand Five Hundred EightyFour Only	L1
161	MSD Pharmaceuticals Pvt. Ltd.	2227	Human Papillomavirus- Each 0.5ml to contain: Human Papillomavirus Quadrivalent (6, 11, 16 , 18 ) Vaccine, Recombinant Packing: 0.5ml Vial/Amp/PFS	1Vial/Amp	Gardasil Mfg. By: Merck Sharp and Dohme B.V., Waarderweg 39 2031, BN, Harleem, Netherlands	0.5ml PFS	2500.00/ 1 Vial/Amp	Rupees Two Thousand Five Hundred Only	L1
161	Samarth Life Sciences Pvt. Ltd.	2323	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 20mg Packing: 1 Vial/Amp	1Vial/Amp	DOCET	1 VIAL	162.09/ 1 Vial/Amp	Rupees One Hundred SixtyTwo Paise Nine Only	L1
161	Naprod Life Sciences Pvt. Ltd.	2323	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 20mg Packing: 1 Vial/Amp	1Vial/Amp	Same as in Item	1 Vial	183.60/ 1 Vial/Amp	Rupees One Hundred EightyThree Paise Sixty Only	L2

ESIC

  
रूप चिकित्सा अधिकारी (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

43

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Getwell Pharma India Private Limited	2323	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 20mg Packing: 1 Vial/Amp	1Vial/Amp	Taxewell 20mg/0.5ml	1 Vial	319.00/ 1 Vial/Amp	Rupees Three Hundred Nineteen Only	L3
161	Samarth Life Sciences Pvt. Ltd.	2324	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 120mg Packing: 1 Vial/Amp	1Vial/Amp	DOCET	1 VIAL	422.10/ 1 Vial/Amp	Rupees Four Hundred TwentyTwo Paise Ten Only	L1
161	Naprod Life Sciences Pvt. Ltd.	2324	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 120mg Packing: 1 Vial/Amp	1Vial/Amp	Same as in Item	1 Vial	505.00/ 1 Vial/Amp	Rupees Five Hundred Five Only	L2
161	Intas Pharmaceuticals Ltd	2324	Docetaxel Inj- Each Vial/Amp to contain: Docetaxel 120mg Packing: 1 Vial/Amp	1Vial/Amp	TAXOCARE 120	1 vial of 6 ml	810.00/ 1 Vial/Amp	Rupees Eight Hundred Ten Only	L3
161	RIVPRA FORMULATION PVT. LTD,	2327	Alfa Ketoanalogue Tab/Cap- Each Tab/Cap to contain: Alpha Ketoanalogue 381mg, L- Histidine 38m, L-Lysine 105mg,L-Threonine 53mg, Tryptophan 23mg, Tyrosine 30mg	1 Tab/Cap	RENOKETOL	10 tabs	12.45/ 1 Tab/Cap	Rupees Twelve Paise FourtyFive Only	L1
161	Intas Pharmaceuticals Ltd	2329	Denosumab Inj- Each PFS to contain: Denosumab 60mg Packing: 1 PFS	1 PFS	OLIMAB	1 PFS	5555.00/ 1 PFS	Rupees Five Thousand Five Hundred FiftyFive Only	L1

*Sagar*  
रूप विजयलाल अग्रवाल (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

44



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Bharat Serums And Vaccines Limited	2334	Anti Rabies Serum Equine Inj- Each ml to contain: Equine Antirabies Immunoglobulin 300 IU Packing: 5ml Vial	1 Vial	EQUIRAB 1500IU/5ML	1 Vial of 5ml	350.00/ 1 Vial	Rupees Three Hundred Fifty Only	L1
161	Pfizer Limited	2336	Pneumococcal Vaccine- Each 0.5ml to contain: Pneumococcal Polysaccharide Conjugate Vaccine (13 Valent) Packing: 1 PFS	1 PFS	PREVENAR 13 Mfg. By: Pfizer Manufacturing Belgium NV, Rijksweg 12, B-2870, Puurs, Belgium	1 PFS	2863.62/ 1 PFS	Rupees Two Thousand Eight Hundred SixtyThree Paise SixtyTwo Only	L1
161	Johnson & Johnson Pvt. Ltd.	2500	Amivantamab Injection-Each ml to contain:Amivantamab 50mg Packing:7ml Vial	1 Vial	Rybrevant® 350 mg Mfg. By: M/s. Cilag AG, , Hochstrasse 201, . Schaffhausen Schaffhausen(Switzerland) - CH-8200	1 Vial	67965.00/ 1 Vial	Rupees SixtySeven Thousand Nine Hundred SixtyFive Only	L1
161	Bharat Serums And Vaccines Limited	2501	Antithymocyte Immunoglobulin Inj. -Each ml to contains:Antithymocyte Immunoglobulin (Equine)-50mg, Packing:5ml vial	1 Vial	THYMOGAM	1 Vial of 5ml	8700.00/ 1 Vial	Rupees Eight Thousand Seven Hundred Only	L1

क.रा.बी.नि.  
ESIC

*Says*  
रजि. वि. नि. आ. यु. क. (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

45

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Merck Specialities Private Limited	2502	Avelumab Inj.-Each ml to contain Avelumab 20mg Packing:10ml vial	1 Vial	Bavencio 200mg/10ml Mfg. By: M/s. Merck Serono S.A., Zone Industrielle de l'Ouriettaz Aubonne Vaud(Switzerland) CH-1170	1 Vial of 10 ml	64543.00/ 1 Vial	Rupees SixtyFour Thousand Five Hundred FourtyThree Only	L1
161	Pfizer Products India Private Limited	2504	Lorlatinib Tablet-Each Tab to contain: Lorlatinib 100mg	1 Tab	LORBRIQUA Mfg. By: M/s Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg, Mooswaldallee 1,Freiburg NA (Germany) -79090	5 Tablets	7057.00/ 1 Tab/Cap	Rupees Seven Thousand FiftySeven Only	L1
161	Bharat Serums And Vaccines Limited	1339a	Human Tetanus Specific Immunoglobulin- Each Vial to contain: Human Tetanus Specific Immunoglobulin 250 Units. Packing:1 Vial	1 Vial	TETGLOB	1 Vial	1045.62/ 1 Vial	Rupees One Thousand Forty Five Paise sixtytwo Only	L1
161	Bharat Serums And Vaccines Limited	1339b	Human Tetanus Specific Immunoglobulin- Each Vial to contain: Human Tetanus Specific Immunoglobulin 500 Units. Packing: 1 Vial	1 Vial	TETGLOB	1 Vial	1575.62/ 1 Vial	Rupees One Thousand Five Hundred Seventy Five Paise sixtytwo Only	L1



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Cipla Ltd.	1454b	Capecitabine Tab/Cap- Each Tab/Cap to contain: Capecitabine 500mg	1 Tab/Cap	Capegard 500	10 Tabs	13.80/ 1 Tab/Cap	Rupees Thirteen Paise Eighty Only	L1
161	Intas Pharmaceuticals Ltd	1454b	Capecitabine Tab/Cap- Each Tab/Cap to contain: Capecitabine 500mg	1 Tab/Cap	CAPSY 500	10 Tab	16.50/ 1 Tab/Cap	Rupees Sixteen Paise Fifty Only	L2
161	Samarth Life Sciences Pvt. Ltd.	1473a	Sunitinib Malate Tab/Cap- Each Tab/Cap to contain: Sunitinib Malate 12.5mg	1 Tab/Cap	SUNISAM 12.5MG	7 CAPS	36.90/ 1 Tab/Cap	Rupees ThirtySix Paise Ninety Only	L1
161	MICRON PHARMACEUTICALS	1476b	Deferasirox Tab/Cap- Each Tab/Cap to contain Deferasirox 400mg	1 Tab/Cap	Same as in Item	6 Tab	7.92/ 1 Tab/Cap	Rupees Seven Paise NinetyTwo Only	L1
161	Bajaj Healthcare Limited	1476b	Deferasirox Tab/Cap- Each Tab/Cap to contain Deferasirox 400mg	1 Tab/Cap	DEFERAJAJ 400	10 Tabs	13.27/ 1 Tab/Cap	Rupees Thirteen Paise TwentySeven Only	L2
161	Intas Pharmaceuticals Ltd	1650a	Filgrastim Inj- Each PFS/Vial to contain: Filgrastim 150 mcg Packing: 1 Vial/PFS	1 PFS/ Vial	NEUKINE 150 mcg	1 PFS	448.89/ 1 PFS/Vial	Rupees Four Hundred FourtyEight Paise EightyNine Only	L1
161	Samarth Life Sciences Pvt. Ltd.	459b	Gemcitabine Inj- Each Vial to contain: Gemcitabine 1gm Packing: 1 Vial	1 Vial	LIFOGEM	1 VIAL	351.09/ 1 Vial	Rupees Three Hundred FiftyOne Paise Nine Only	L1
161	Naprod Life Sciences Pvt. Ltd.	459b	Gemcitabine Inj- Each Vial to contain: Gemcitabine 1gm Packing: 1 Vial	1 Vial	Same as in Item	1 Vial	594.00/ 1 Vial	Rupees Five Hundred NinetyFour Only	L2

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	Getwell Pharma India Private Limited	459b	Gemcitabine Inj- Each Vial to contain: Gemcitabine 1gm Packing: 1 Vial	1 Vial	Gemwel 1gm	1 Vial	919.00/ 1 Vial	Rupees Nine Hundred Nineteen Only	L3
161	Naprod Life Sciences Pvt. Ltd.	487a	Paclitaxel Inj- Each Vial to contain: Paclitaxel 100mg Packing: 1 Vial	1 Vial	Same as in Item	1 Vial	315.00/ 1 Vial	Rupees Three Hundred Fifteen Only	L1
161	Getwell Pharma India Private Limited	487a	Paclitaxel Inj- Each Vial to contain: Paclitaxel 100mg Packing: 1 Vial	1 Vial	Pacliwel 100mg/16.7ml	1 Vial	425.00/ 1 Vial	Rupees Four Hundred TwentyFive Only	L2
161	Naprod Life Sciences Pvt. Ltd.	488a	Carboplatin Inj- Each Vial to contain: Carboplatin 150mg Packing: 1 Vial	1 Vial	Naproplat 150mg/15ml	1 Vial	531.00/ 1 Vial	Rupees Five Hundred ThirtyOne Only	L1
161	Getwell Pharma India Private Limited	488a	Carboplatin Inj- Each Vial to contain: Carboplatin 150mg Packing: 1 Vial	1 Vial	Carbowel 150mg/15ml	1 Vial	783.65/ 1 Vial	Rupees Seven Hundred EightyThree Paise SixtyFive Only	L2
161	Naprod Life Sciences Pvt. Ltd.	488b	Carboplatin Inj- Each Vial to contain: Carboplatin 450mg Packing:1 Vial	1 Vial	Same as in Item	1 Vial	1530.00/ 1 Vial	Rupees One Thousand Five Hundred Thirty Only	L1
161	Getwell Pharma India Private Limited	488b	Carboplatin Inj- Each Vial to contain: Carboplatin 450mg Packing:1 Vial	1 Vial	Carbowel 450mg/45ml	1 Vial	2350.25/ 1 Vial	Rupees Two Thousand Three Hundred Fifty Paise TwentyFive Only	L2

  
उप-चिकित्सा आरक्षक (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

48



RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores accepted	Packing Offered by firm	Rate/ Unit	Rate/ Unit (in words)	Preference
161	TROIKAA PHARMACEUTICALS LIMITED	578b	Alendronate Tab/Cap- Each Tab/Cap to contain: Alendronate 70mg	1 Tab/Cap	BIFOSA 70	4 Tab	14.56/ 1 Tab/Cap	Rupees Fourteen Paise FiftySix Only	L1

END OF RATE CONTRACT



*Saini*  
रज्य चिकित्सा आयुक्त (आर.सी./पी.सी.)  
Deputy Medical Commissioner (RC/PC)

क.रा.बी.नि.  
ESIC